Skip to main content
Matthew Rettig, MD, Oncology, Los Angeles, CA

Matthew Rettig MD


Associate Professor, Medicine, UCLA School of Medicine

Join to View Full Profile
  • 11301 Wilshire Blvd., 111HLos Angeles, CA 90073

  • Phone+1 310-268-3622

  • Fax+1 310-268-3622

Dr. Rettig is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1993 - 1996
  • University of Washington
    University of WashingtonResidency, Internal Medicine, 1991 - 1993
  • University of Southern California/Los Angeles General Medical Center (USC/LA General)
    University of Southern California/Los Angeles General Medical Center (USC/LA General)Internship, Internal Medicine, 1990 - 1991
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1990

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1993 - 2027
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Functional Profiling of Circulating Tumor Cells with an Integrated Vortex Capture and Single-Cell Protease Activity Assay  
    Steven M Dubinett, Matthew B Rettig, Proceedings of the National Academy of Sciences

Press Mentions

  • Landmark VA Study Uncovers Gene Variant Linked to Prostate Cancer
    Landmark VA Study Uncovers Gene Variant Linked to Prostate CancerFebruary 19th, 2025
  • INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans
    INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to VeteransJanuary 28th, 2025
  • INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans
    INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to VeteransJanuary 28th, 2025
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: